ZhiHai Wu

ZhiHai Wu

Auto-generated profile, based on publicly available information

ZhiHai Wu

Department of Antibody Discovery and Protein Engineering, Innovent Guoqing Academy, Suzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in mAbs
Verified
Journal Article
Open access
JWJie Wang
Jie Wang
KFKeke Fei
Keke Fei
HJHua Jing
Hua Jing
ZWZhihai Wu
Zhihai Wu
WWWeiwei Wu
Weiwei Wu
JLJunjian Liu
Junjian Liu
Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety of malignancies. Sintilimab, a highly selective, fully human monoclonal antibody (mAb), blocks the interaction of PD-1 and its ligands and has demonstrated clinical benefit in various clinical studies. Here, we evaluated the affinity of sintilimab to human PD-1 by surface plasmon resonance and mesoscale discovery and evaluated PD-1 receptor occupancy and anti-tumor efficacy of sintilimab in a humanized NOD/Shi-scid-IL2rgamma (null) (NOG) mouse model. We also assessed the receptor occupancy and immunogenicity of sintilimab from clinical studies in humans (9 patients with advanced solid tumor and 381 patients from 4 clinical studies, respectively). Sintilimab bound to human PD-1 with greater affinity than nivolumab (Opdivo®, MDX-1106) and pembrolizumab (Keytruda®, MK-3475). The high affinity of sintilimab is explained by its distinct structural binding mode to PD-1. The pharmacokinetic behavior of sintilimab did not show any significant differences compared to the other two anti-PD-1 mAbs. In the humanized NOG mouse model, sintilimab showed superior PD-1 occupancy on circulating T cells and a stronger anti-tumor effect against NCI-H292 tumors. The strong anti-tumor response correlated with increased interferon-γ-secreting, tumor-specific CD8+ T cells, but not with CD4+ Tregs in tumor tissue. Pharmacodynamics testing indicated a sustained mean occupancy of ≥95% of PD-1 molecules on circulating T cells in patients following sintilimab infusion, regardless of infusion dose. Sintilimab infusion was associated with 0.52% (2/381 patients) of anti-drug antibodies and 0.26% (1/381 patients) neutralizing antibodies. These data validate sintilimab as a novel, safe, and efficacious anti-PD-1 mAb for cancer immunotherapy.

1 January 2021 in OncoImmunology
Verified
Journal Article
Open access
HJHaiping Jiang
Haiping Jiang
HNHaiqing Ni
Haiqing Ni
PZPan Zhang
Pan Zhang
XGXiaoli Guo
Xiaoli Guo
MWMin Wu
Min Wu
JLJunjian Liu
Junjian Liu
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it. Resistance to cancer immunotherapy can be mediated by additional immune checkpoints. We hypothesized that co-targeting of PD-L1 and lymphocyte-activation gene 3 (LAG-3) could provide an alternative therapeutic approach. Here, we developed IBI323, a dual blockade bispecific antibody targeting PD-L1 and LAG-3. We assessed the binding affinity, blocking activity, cell bridging effect, and immunomodulation function of IBI323 using in vitro assays. We also evaluated, in two humanized mouse models, anti-tumor effects and antitumor T cell immunity induced by IBI323. IBI323 bound to PD-L1 and LAG-3 with similar potency as its parental antibodies and blocked the interaction of PD-1/PD-L1, CD80/PD-L1, and LAG-3/MHC-II. Moreover, IBI323 mediated the bridging of PD-L1+ cells and LAG-3+ cells and demonstrated superior immune stimulatory activity compared to each parent antibody in mixed leukocyte reaction. In PD-L1/LAG-3 double knock-in mice bearing human PD-L1 knock-in MC38 tumors, IBI323 showed stronger anti-tumor activity compared to each parental antibody. The better antitumor response correlated with increased tumor-specific CD8+ and CD4+ T cells. IBI323 also induced stronger anti-tumor effect against established A375 tumors compared with combination in mice reconstituted with human immune cells. Collectively, these data demonstrated that IBI323 preserved the blockade activities of parental antibodies while processing a novel cell bridging function. Based on the encouraging preclinical results, IBI323 has significant value in further clinical development.

29 September 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
The CD47/SIRPα axis serves as a “do not eat me” signal, protecting normal cells from phagocytosis, but in the meantime, enabling immune evasion by tumor cells. Whereas substantial progress has been made in developing CD47 antagonists, achieving a balance between hematotoxicity and antitumor efficacy remains a critical challenge. In this study, we demonstrated that the bivalent anti-CD47 antibody, Hu5F9, caused severe anemia in both human CD47 knock-in mice lacking the CD47/SIRPα signal and human CD47/SIRPα double knock-in mice with complete signal, suggesting the CD47/SIRPα signal is not essential. Moreover, the single-arm CD47 antibody Hu5F9/gp120 exhibited only mild red blood cell (RBC) destruction in vitro and in vivo. These findings reveal that RBC toxicity induced by anti-CD47 antibodies is determined by the bivalency of the antibody rather than the CD47/SIRPα signal engagement. Based on this, we engineered TJH2201, a novel anti-CD47 antibody that avoids RBC agglutination while retaining high-affinity CD47 binding, robust signaling blockade, and enhanced pro-phagocytosis activity in vitro. In xenograft models with Raji and MV-4-11 cells, TJH2201 demonstrated potent antitumor activity without inducing body weight loss. These results suggest that TJH2201 is a promising CD47 antagonist that balances antitumor efficacy and hematologic safety, providing a new therapeutic approach for CD47-expressing malignancies.

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S3: Binding ability of Hu5F9/B2B, and their respective parent antibodies.

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S12: In vivo PK profiles of TJH2201 in Balb/c mice.

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S9: Microscopic images of in vitro RBC agglutination induced by TJH2201 at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100 µm